Universe Pharmaceuticals Inc.(UPC)Earnings, Financials & Key Ratios
UPC•NASDAQ
$2.82
$2M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryTraditional Chinese medicine producers
AboutUniverse Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.Show more
- Revenue$18M-22.4%
- EBITDA-$2M+68.2%
- Net Income-$4M+57.9%
- EPS (Diluted)-1055.75+26.5%
- Gross Margin35.28%+33.8%
- EBITDA Margin-13.43%+59.0%
- Operating Margin-16.33%+53.1%
- Net Margin-20.56%+45.8%
- ROE-7.23%+64.8%
- ROIC-7.84%+58.5%
- Debt/Equity0.16-6.1%
- Interest Coverage-14.83+47.4%
UPC Key Insights
Universe Pharmaceuticals Inc. (UPC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 42.8% through buybacks
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 10.3% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
UPC Price & Volume
Universe Pharmaceuticals Inc. (UPC) stock price & volume — 10-year historical chart
Loading chart...
UPC Growth Metrics
Universe Pharmaceuticals Inc. (UPC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-10.27%
3 Years-23.66%
TTM-43.57%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM5.34%
Return on Capital
10 Years29.81%
5 Years-2.29%
3 Years-10.74%
Last Year-5.62%
UPC Peer Comparison
Universe Pharmaceuticals Inc. (UPC) competitors in Traditional Chinese medicine producers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HCWB | 13.6M | 0.35 | -0.46 | -9.68% | -28.56% | -8.97% | ||
 XTLB | 357.58K | 3.25 | -0.34 | -227.72% | -25.53% | 0.03 | ||
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 CPRX | 3.74B | 30.52 | 18.17 | 19.78% | 36.39% | 22.46% | 0.00 | |
 TLPH | 42.92M | 0.87 | -2.56 | -510.36% | -118.01% | |||
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 | |
 HROW | 1.5B | 40.27 | -287.64 | 36.41% | -1.89% | -10.07% | 4.84 | |
 MCK | 91.09B | 743.67 | 28.91 | 16.22% | 1.09% |
Compare UPC vs Peers
Universe Pharmaceuticals Inc. (UPC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
UPC Income Statement
Universe Pharmaceuticals Inc. (UPC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 28.51M | 33.23M | 30.7M | 47.98M | 40.14M | 32.31M | 23.02M | 17.86M |
| Revenue Growth % | - | 16.54% | -7.6% | 56.27% | -16.34% | -19.52% | -28.74% | -22.44% |
| Cost of Goods Sold | 15.11M | 19.82M | 16.61M | 22.66M | 18.25M | 21.99M | 16.95M | 11.56M |
| COGS % of Revenue | 52.97% | 59.65% | 54.1% | 47.22% | 45.47% | 68.07% | 73.63% | 64.72% |
| Gross Profit | 13.41M▲ 0% | 13.41M▼ 0.0% | 14.09M▲ 5.1% | 25.33M▲ 79.7% | 21.89M▼ 13.6% | 10.32M▼ 52.9% | 6.07M▼ 41.1% | 6.3M▲ 3.8% |
| Gross Margin % | 47.03% | 40.35% | 45.9% | 52.78% | 54.53% | 31.93% | 26.37% | 35.28% |
| Gross Profit Growth % | - | -0.01% | 5.12% | 79.7% | -13.56% | -52.88% | -41.14% | 3.78% |
| Operating Expenses | 3.65M | 3.36M | 3.74M | 11.74M | 28.91M | 13.84M | 14.09M | 9.22M |
| OpEx % of Revenue | 12.8% | 10.1% | 12.19% | 24.46% | 72.02% | 42.84% | 61.2% | 51.61% |
| Selling, General & Admin | 2.39M | 2.29M | 2.8M | 6.27M | 21.3M | 9M | 10.44M | 8M |
| SG&A % of Revenue | 8.36% | 6.9% | 9.1% | 13.07% | 53.05% | 27.86% | 45.36% | 44.81% |
| Research & Development | 789.38K | 618.44K | 583.13K | 5.47M | 7.62M | 4.86M | 3.03M | 671.76K |
| R&D % of Revenue | 2.77% | 1.86% | 1.9% | 11.39% | 18.99% | 15.04% | 13.16% | 3.76% |
| Other Operating Expenses | 474.63K | 445.77K | 365.77K | 0 | -7.53K | -17.53K | 616.27K | 542.97K |
| Operating Income | 9.66M▲ 0% | 9.75M▲ 1.0% | 10.25M▲ 5.1% | 13.59M▲ 32.6% | -7.02M▼ 151.7% | -3.53M▲ 49.8% | -8.02M▼ 127.4% | -2.92M▲ 63.6% |
| Operating Margin % | 33.87% | 29.35% | 33.39% | 28.32% | -17.49% | -10.92% | -34.83% | -16.33% |
| Operating Income Growth % | - | 1% | 5.12% | 32.56% | -151.65% | 49.76% | -127.4% | 63.64% |
| EBITDA | 10.11M | 10.17M | 10.66M | 14.04M | -6.49M | -3.02M | -7.53M | -2.4M |
| EBITDA Margin % | 35.45% | 30.61% | 34.72% | 29.25% | -16.16% | -9.34% | -32.72% | -13.43% |
| EBITDA Growth % | - | 0.62% | 4.82% | 31.66% | -146.2% | 53.47% | -149.64% | 68.16% |
| D&A (Non-Cash Add-back) | 452.73K | 418.43K | 410.08K | 446.88K | 533.95K | 508.79K | 485.73K | 517.43K |
| EBIT | 9.68M | 9.78M | 10.22M | 13.78M | -6.93M | -3.69M | -7.84M | -3.44M |
| Net Interest Income | -164.92K | -129.27K | -123.76K | -101.6K | -162.4K | -156.79K | -278.17K | -232.04K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 164.92K | 129.27K | 123.76K | 101.6K | 162.4K | 156.79K | 278.17K | 232.04K |
| Other Income/Expense | -138.28K | -99.77K | -151.29K | 57.51K | -545.35K | -413.77K | -100.75K | -756.14K |
| Pretax Income | 9.52M▲ 0% | 9.65M▲ 1.4% | 10.1M▲ 4.6% | 13.65M▲ 35.1% | -7.98M▼ 158.5% | -3.94M▲ 50.6% | -8.12M▼ 106.1% | -3.67M▲ 54.8% |
| Pretax Margin % | 33.38% | 29.05% | 32.9% | 28.44% | -19.89% | -12.2% | -35.27% | -20.56% |
| Income Tax | 1.92M | 2.1M | 2.54M | 2.36M | 752.42K | 2.25M | 606.7K | 0 |
| Effective Tax Rate % | 20.12% | 21.77% | 25.17% | 17.28% | -9.42% | -57.19% | -7.47% | 0% |
| Net Income | 7.6M▲ 0% | 7.55M▼ 0.7% | 7.56M▲ 0.1% | 11.32M▲ 49.8% | -8.74M▼ 177.2% | -6.16M▲ 29.5% | -8.73M▼ 41.6% | -3.67M▲ 57.9% |
| Net Margin % | 26.66% | 22.73% | 24.62% | 23.59% | -21.76% | -19.08% | -37.9% | -20.56% |
| Net Income Growth % | - | -0.68% | 0.09% | 49.77% | -177.18% | 29.46% | -41.61% | 57.92% |
| Net Income (Continuing) | 7.6M | 7.55M | 7.56M | 11.29M | -8.74M | -6.19M | -8.73M | -3.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1303.36▲ 0% | 1294.54▼ 0.7% | 1295.70▲ 0.1% | 2147.18▲ 65.7% | -1475.02▼ 168.7% | -1040.53▲ 29.5% | -1436.12▼ 38.0% | -1055.75▲ 26.5% |
| EPS Growth % | - | -0.68% | 0.09% | 65.72% | -168.7% | 29.46% | -38.02% | 26.49% |
| EPS (Basic) | 1303.36 | 1294.54 | 1295.70 | 2147.18 | -1475.02 | -1040.53 | -1436.12 | -1055.75 |
| Diluted Shares Outstanding | 5.83K | 5.83K | 5.83K | 5.27K | 5.92K | 5.92K | 6.08K | 3.48K |
| Basic Shares Outstanding | 5.83K | 5.83K | 5.83K | 5.27K | 5.92K | 5.92K | 6.08K | 3.48K |
| Dividend Payout Ratio | 40.25% | 211.95% | - | - | - | - | - | - |
UPC Balance Sheet
Universe Pharmaceuticals Inc. (UPC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 21.96M | 12.23M | 22.84M | 50.48M | 41.51M | 36.81M | 51.64M | 53.6M |
| Cash & Short-Term Investments | 6.19M | 3.18M | 10.06M | 21.8M | 18.86M | 18.5M | 29.5M | 33.59M |
| Cash Only | 6.19M | 3.18M | 10.06M | 8.08M | 5.71M | 5.29M | 29.5M | 33.59M |
| Short-Term Investments | 0 | 0 | 0 | 13.73M | 13.15M | 13.22M | 0 | 0 |
| Accounts Receivable | 7.64M | 6.42M | 10.87M | 15.81M | 15.18M | 10.73M | 17.88M | 13.19M |
| Days Sales Outstanding | 97.76 | 70.53 | 129.24 | 120.27 | 138.06 | 121.21 | 283.4 | 269.5 |
| Inventory | 8.12M | 2.62M | 1.91M | 2.46M | 2.21M | 3.34M | 1.74M | 2.19M |
| Days Inventory Outstanding | 196.22 | 48.16 | 41.89 | 39.67 | 44.13 | 55.48 | 37.4 | 69.26 |
| Other Current Assets | 0 | 0 | 443.71K | 174.05K | 1.72M | 626.24K | 852.42K | 39.94K |
| Total Non-Current Assets | 6.12M | 5.61M | 5.52M | 19.66M | 18.03M | 16.48M | 16.32M | 15.7M |
| Property, Plant & Equipment | 5.08M | 4.57M | 4.43M | 15.39M | 13.58M | 14.99M | 15.34M | 14.7M |
| Fixed Asset Turnover | 5.62x | 7.28x | 6.93x | 3.12x | 2.96x | 2.16x | 1.50x | 1.21x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 183.58K | 171.61K | 174.78K | 178.48K | 157.45K | 148.58K | 262.88K | 296.79K |
| Long-Term Investments | 728K | 700.5K | 735K | 744.92K | 702.89K | 685.31K | 712.49K | 702.35K |
| Other Non-Current Assets | 0 | 0 | 0 | 2.48M | 2.25M | 0 | 0 | 0 |
| Total Assets | 28.08M▲ 0% | 17.84M▼ 36.5% | 28.8M▲ 61.5% | 70.14M▲ 143.5% | 59.54M▼ 15.1% | 53.29M▼ 10.5% | 67.95M▲ 27.5% | 69.3M▲ 2.0% |
| Asset Turnover | 1.02x | 1.86x | 1.07x | 0.68x | 0.67x | 0.61x | 0.34x | 0.26x |
| Asset Growth % | - | -36.48% | 61.49% | 143.52% | -15.12% | -10.5% | 27.52% | 1.99% |
| Total Current Liabilities | 18.4M | 5.45M | 8M | 11.21M | 13.1M | 13.75M | 20.31M | 13.17M |
| Accounts Payable | 2.94M | 1.94M | 2.69M | 5.31M | 3.08M | 4.59M | 4.91M | 1.67M |
| Days Payables Outstanding | 71 | 35.67 | 59.14 | 85.56 | 61.5 | 76.1 | 105.82 | 52.73 |
| Short-Term Debt | 2.62M | 2.52M | 2.65M | 4.33M | 3.94M | 5.48M | 5.86M | 9.26M |
| Deferred Revenue (Current) | 893.51K | 0 | 0 | 0 | 0 | 0 | 0 | 40.71K |
| Other Current Liabilities | -893.51K | 0 | 956.49K | 0 | 3.38M | 0 | 0 | 0 |
| Current Ratio | 1.19x | 2.24x | 2.85x | 4.50x | 3.17x | 2.68x | 2.54x | 4.07x |
| Quick Ratio | 0.75x | 1.76x | 2.62x | 4.28x | 3.00x | 2.43x | 2.46x | 3.90x |
| Cash Conversion Cycle | 222.98 | 83.02 | 111.99 | 74.39 | 120.68 | 100.6 | 214.98 | 286.03 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 7.01M | 0 | 2.14M | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 2.14M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 18.4M | 5.45M | 8M | 11.21M | 13.1M | 13.75M | 22.45M | 13.17M |
| Total Debt | 2.62M | 2.52M | 2.65M | 4.33M | 3.94M | 5.48M | 7.99M | 9.26M |
| Net Debt | -3.57M | -655.52K | -7.41M | -3.74M | -1.78M | 197.21K | -21.5M | -24.34M |
| Debt / Equity | 0.27x | 0.20x | 0.13x | 0.07x | 0.08x | 0.14x | 0.18x | 0.16x |
| Debt / EBITDA | 0.26x | 0.25x | 0.25x | 0.31x | - | - | - | - |
| Net Debt / EBITDA | -0.35x | -0.06x | -0.70x | -0.27x | - | - | - | - |
| Interest Coverage | 58.71x | 75.67x | 82.61x | 135.63x | -42.68x | -23.55x | -28.19x | -14.83x |
| Total Equity | 9.68M▲ 0% | 12.38M▲ 27.9% | 20.8M▲ 68.0% | 58.93M▲ 183.3% | 46.44M▼ 21.2% | 39.53M▼ 14.9% | 45.5M▲ 15.1% | 56.13M▲ 23.4% |
| Equity Growth % | - | 27.91% | 67.98% | 183.3% | -21.2% | -14.88% | 15.1% | 23.35% |
| Book Value per Share | 1659.79 | 2123.10 | 3566.42 | 11178.75 | 7841.01 | 6674.44 | 7487.73 | 16138.44 |
| Total Shareholders' Equity | 9.68M | 12.38M | 20.8M | 58.93M | 46.44M | 39.53M | 45.5M | 56.13M |
| Common Stock | 50K | 50K | 50K | 67.97K | 67.97K | 67.97K | 482.4K | 6.34M |
| Retained Earnings | 2.83M | 6.18M | 13.74M | 25.06M | 16.32M | 10.16M | -10.17M | -13.84M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3.12M | 2.47M | 3.33M | 4.53M | 772.83K | 26.27K | 1.33M | 626.01K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
UPC Cash Flow Statement
Universe Pharmaceuticals Inc. (UPC) cash flow — operating, investing & free cash flow history
| Line item | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 4.46M | 13.2M | 6.12M | -2.06M | -1.31M | 1.12M | -9.51M | -5.05M |
| Operating CF Margin % | 15.63% | 39.74% | 19.92% | -4.28% | -3.27% | 3.47% | -41.29% | -28.29% |
| Operating CF Growth % | - | 196.34% | -53.69% | -133.62% | 36.17% | 185.35% | -948.75% | 46.86% |
| Net Income | 7.6M | 7.55M | 7.56M | 11.32M | -7.91M | -6.58M | -8.73M | -3.67M |
| Depreciation & Amortization | 452.73K | 418.43K | 410.08K | 446.88K | 533.95K | 508.79K | 485.73K | 517.43K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 17.54K | -39.63K | -9.89K | -668.34K | -542.38K | 1.57M | 606.7K | 0 |
| Other Non-Cash Items | -85.19K | 112.79K | 22.71K | -468.17K | 5.97K | -45.74K | 186.19K | 370.6K |
| Working Capital Changes | -3.53M | 5.16M | -1.87M | -12.69M | 6.6M | 5.67M | -2.06M | -2.27M |
| Change in Receivables | -2.82M | 665.49K | -4.11M | -3.87M | -1.55M | 4.72M | -1.71M | 3.13M |
| Change in Inventory | -327.26K | 5.59M | 888.61K | -451.63K | 16.59K | -1.18M | 1.64M | -474.63K |
| Change in Payables | 265.17K | -924.44K | 639.43K | 2.46M | -1.9M | 1.64M | 143.75K | -3.13M |
| Cash from Investing | -145.09K | -86.03K | -51.8K | -27.06M | -3.91M | -44.17K | -361.29K | -341.81K |
| Capital Expenditures | -145.09K | -86.32K | -51.8K | -13.53M | -93.7K | -44.17K | -245.8K | -266.77K |
| CapEx % of Revenue | 0.51% | 0.26% | 0.17% | 28.2% | 0.23% | 0.14% | 1.07% | 1.49% |
| Acquisitions | 0 | 291 | 0 | 26.62M | -3.81M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -26.62M | 523 | 0 | -115.49K | -75.04K |
| Cash from Financing | -4.91M | -16M | 470.14K | 26.58M | 3.32M | -1.39M | 33.95M | 9.73M |
| Debt Issued (Net) | -1.85M | 1.14K | 911.2K | 624.35K | 3.32M | -1.39M | 8.95M | -5.27M |
| Equity Issued (Net) | 0 | 0 | 0 | 28.75M | 0 | 0 | 25M | 15M |
| Dividends Paid | -3.06M | -16M | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -441.06K | -2.79M | 0 | 0 | 0 | 0 |
| Net Change in Cash | -793.24K▲ 0% | -3.01M▼ 279.8% | 6.88M▲ 328.4% | -1.98M▼ 128.8% | -2.37M▼ 19.5% | -426.21K▲ 82.0% | 24.21M▲ 5780.9% | 4.09M▼ 83.1% |
| Free Cash Flow | 4.31M▲ 0% | 13.12M▲ 204.3% | 6.06M▼ 53.8% | -15.59M▼ 357.1% | -1.41M▲ 91.0% | 1.08M▲ 176.5% | -9.87M▼ 1017.3% | -5.4M▲ 45.3% |
| FCF Margin % | 15.12% | 39.48% | 19.75% | -32.49% | -3.5% | 3.33% | -42.87% | -30.23% |
| FCF Growth % | - | 204.31% | -53.78% | -357.07% | 90.98% | 176.52% | -1017.34% | 45.29% |
| FCF per Share | 738.99 | 2248.83 | 1039.49 | -2956.58 | -237.39 | 181.65 | -1624.12 | -1552.47 |
| FCF Conversion (FCF/Net Income) | 0.59x | 1.75x | 0.81x | -0.18x | 0.15x | -0.18x | 1.09x | 1.38x |
| Interest Paid | 183.07K | 135.72K | 157.53K | 149.3K | 199.85K | 190.18K | 304.52K | 289.38K |
| Taxes Paid | 1.7M | 2.26M | 2.17M | 3.27M | 2.75M | 863.8K | 0 | 0 |
UPC Key Ratios
Universe Pharmaceuticals Inc. (UPC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 78.53% | 68.45% | 45.55% | 28.39% | -16.58% | -14.34% | -20.53% | -7.23% |
| Return on Invested Capital (ROIC) | 118.49% | 82% | 61.22% | 29.72% | -10.54% | -6.27% | -18.88% | -7.84% |
| Gross Margin | 47.03% | 40.35% | 45.9% | 52.78% | 54.53% | 31.93% | 26.37% | 35.28% |
| Net Margin | 26.66% | 22.73% | 24.62% | 23.59% | -21.76% | -19.08% | -37.9% | -20.56% |
| Debt / Equity | 0.27x | 0.20x | 0.13x | 0.07x | 0.08x | 0.14x | 0.18x | 0.16x |
| Interest Coverage | 58.71x | 75.67x | 82.61x | 135.63x | -42.68x | -23.55x | -28.19x | -14.83x |
| FCF Conversion | 0.59x | 1.75x | 0.81x | -0.18x | 0.15x | -0.18x | 1.09x | 1.38x |
| Revenue Growth | - | 16.54% | -7.6% | 56.27% | -16.34% | -19.52% | -28.74% | -22.44% |
UPC Frequently Asked Questions
Universe Pharmaceuticals Inc. (UPC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Universe Pharmaceuticals Inc. (UPC) reported $40.9M in revenue for fiscal year 2025. This represents a 43% increase from $28.5M in 2018.
Universe Pharmaceuticals Inc. (UPC) saw revenue decline by 22.4% over the past year.
Universe Pharmaceuticals Inc. (UPC) reported a net loss of $12.4M for fiscal year 2025.
Dividend & Returns
Universe Pharmaceuticals Inc. (UPC) has a return on equity (ROE) of -7.2%. Negative ROE indicates the company is unprofitable.
Universe Pharmaceuticals Inc. (UPC) had negative free cash flow of $15.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More UPC
Universe Pharmaceuticals Inc. (UPC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates